• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

    1.765 -0.005 (-0.28%)
    Streaming Delayed Price Updated: 11:01 AM EDT, Jun 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 179,818
    Open 1.760
    Bid (Size) 1.760 (2,000)
    Ask (Size) 1.770 (4,600)
    Prev. Close 1.770
    Today's Range 1.760 - 1.820
    52wk Range 1.400 - 12.25
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
    From enGene Therapeutics Inc.
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
    From Pomerantz LLP
    Via GlobeNewswire

    Performance

    YTD
    -80.1%
    -80.1%
    1 Month
    +0.3%
    +0.3%
    3 Month
    -74.6%
    -74.6%
    6 Month
    -81.4%
    -81.4%
    1 Year
    -45.9%
    -45.9%

    More News

    Read More
    News headline image
    Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
    Via The Motley Fool
    News headline image
    Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
    Via The Motley Fool
    News headline image
    ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Unusual volume stocks are being observed in Monday's session. ↗
    Via Chartmill
    News headline image
    enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain ↗
    Via MarketBeat
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Thursday? ↗
    Via Chartmill
    News headline image
    enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
    From enGene Therapeutics Inc.
    Via Business Wire
    News headline image
    enGene Announces Name Change to enGene Therapeutics Inc.
    From enGene Therapeutics Inc.
    Via Business Wire
    News headline image
    This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
    Via The Motley Fool
    News headline image
    enGene Reports First Quarter 2026 Financial Results and Provides Business Update
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    enGene to Participate in Upcoming Investor Conferences
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    enGene Reports Full Year 2025 Financial Results and Provides Business Update
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
    From enGene Holdings Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is enGene Therapeutics Inc. - Common Stock publicly traded?
    Yes, enGene Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does enGene Therapeutics Inc. - Common Stock trade on?
    enGene Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for enGene Therapeutics Inc. - Common Stock?
    The ticker symbol for enGene Therapeutics Inc. - Common Stock is ENGN on the Nasdaq Stock Market
    What is the current price of enGene Therapeutics Inc. - Common Stock?
    The current price of enGene Therapeutics Inc. - Common Stock is 1.765
    When was enGene Therapeutics Inc. - Common Stock last traded?
    The last trade of enGene Therapeutics Inc. - Common Stock was at 06/26/26 11:01 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.